SCHEMBL1635260

SCHEMBL1635260

Cc1c2nc3ccc(N)cc3oc-2cc(=O)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.44
KDM4E B2RXH2 7/20 0.44
NPC1 O15118 6/20 0.44
ALDH1A1 P00352 6/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
MAPT P10636 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
HPGD P15428 4/20 0.44
GLA P06280 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
RECQL P46063 1/20 0.40
SRC P12931 2/20 0.39
EGFR P00533 1/20 0.39
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20362084 0.81 MAPT (0.52) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL3275224 0.79 KMT2A (0.62) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL1635790 0.77 SMN1; SMN2 (0.44) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL3666115 0.77 RAB9A (0.46) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL1636725 0.76 SRC (0.47) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL13338326 0.75 LCK (0.52) RAB9AKDM4ENPC1ALDH1A1MEN1
SCHEMBL1719631 0.74 TERT (0.43) RAB9AKDM4ENPC1ALDH1A1MEN1
Alanine SCHEMBL3274115 0.72 PTPRA (0.58) RAB9AKDM4ENPC1ALDH1A1MEN1
Alanine SCHEMBL3281125 0.72 PTPRA (0.58) RAB9AKDM4ENPC1ALDH1A1MEN1
Alanine SCHEMBL3282143 0.72 PTPRA (0.58) RAB9AKDM4ENPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786828-B1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX SA (FR) 2012-01-11 EP disclosed
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed
EP-1786828-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY BIOMERIEUX (FR) 2007-05-23 EP disclosed
WO-2006030119-A1 NOVEL ENZYMATIC SUBSTRATES DERIVED FROM PHENOXAZINONE AND THEIR USE AS DEVELOPER IN DETECTION OF MICRO-ORGANISM WITH PEPTIDASE ACTIVITY bioMérieux (FR) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP RAB9A 4572/4885KDM4E 2742/4885NPC1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.